Login to Your Account

Trabo-gedy for Inotek: Phase III glaucoma drug bested by placebo

By Michael Fitzhugh
Staff Writer

Tuesday, January 3, 2017

An experimental glaucoma drug developed by Inotek Pharmaceuticals Corp. to augment the eye’s natural method of reducing IOP failed to prove itself better than a placebo at all 12 time points of the pivotal phase III study Matrx-1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription